ABOUT ALLEN BIOTECHNOLOGY CO
Biology is a design problem. We treat it like one.
Founded by structural biologists and machine-learning researchers, Allen
Biotechnology Co exists to shorten the distance between a scientific insight
and a working therapeutic.
OUR MISSION
Make rational biologic design the default, not the exception
Most therapeutic candidates still fail late, after years of investment, because early design choices weren’t grounded in structure. We build the computational and experimental infrastructure that lets teams make those choices correctly the first time – de-risking programs before they reach the clinic.
WHAT GUIDES US
Principles over process
A model is only as good as the wet-lab data that validates it. We test relentlessly.
Partnerships are structured so our success and our collaborators’ success are the same outcome.
Speed with rigor We move quickly because our processes are disciplined, not despite it.
Our Path
From a two-person lab to a fulldiscovery platform
2018
Founded
Started in a shared lab space with a single structure-prediction model and one target.
2020 First platform partner
Signed our first co-development agreement and opened an automated screening facility.
2023
Clinic-ready candidate
Advanced our first internally discovered oncology candidate into IND enabling studies.
2026
140+ team members
Now running 34 active programs across oncology, immunology, and rare disease.
LEADERSHIP
A team spanning structural biologyand machine learning
Dr. Maya Allen
co-founder
& CEO – structural
biology,ex-academic
Dr. Ravi Kapoor
Co-founder & CSO -computational
protein design
Elena Farrow
VP, Process
Development
– biologics
manufacturing
Dr. Sam Okoye
Translational Science -clinical
development